During the last session, Artiva Biotherapeutics Inc (NASDAQ:ARTV)’s traded shares were 0.29 million. At the end of the trading day, the stock’s price was $2.24, reflecting an intraday loss of -2.61% or -$0.06. The 52-week high for the ARTV share is $17.31, that puts it down -672.77 from that peak though still a striking 20.54% gain since the share price plummeted to a 52-week low of $1.78. The company’s market capitalization is $54.58M, and the average intraday trading volume over the past 10 days was 1.21 million shares, and the average trade volume was 278.58K shares over the past three months.
Artiva Biotherapeutics Inc (NASDAQ:ARTV) trade information
Artiva Biotherapeutics Inc (ARTV) registered a -2.61% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.61% in intraday trading to $2.24, hitting a weekly high. The stock’s 5-day price performance is 21.74%, and it has moved by -49.55% in 30 days. The short interest in Artiva Biotherapeutics Inc (NASDAQ:ARTV) is 1.08 million shares and it means that shorts have 7.85 day(s) to cover.
The consensus price target of analysts on Wall Street is $20.5, which implies an increase of 89.07% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $23 respectively. As a result, ARTV is trading at a discount of -926.79% off the target high and -703.57% off the low.
Artiva Biotherapeutics Inc (ARTV) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -64.01%. While earnings are projected to return 49.54% in 2025, the next five years will return 21.09% per annum.
ARTV Dividends
Artiva Biotherapeutics Inc is due to release its next quarterly earnings on 2025-Mar-23. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Artiva Biotherapeutics Inc (NASDAQ:ARTV)’s Major holders
Artiva Biotherapeutics Inc insiders own 22.63% of total outstanding shares while institutional holders control 90.85%, with the float percentage being 117.43%.
Also, the Mutual Funds coming in first place with the largest holdings of Artiva Biotherapeutics Inc (ARTV) shares are SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that SMALLCAP WORLD FUND INC owns about 915.39 shares. This amounts to just over 3.76 percent of the company’s overall shares, with a $2.05 million market value. The same data shows that the other fund manager holds slightly less at 540.17, or about 2.22% of the stock, which is worth about $1.21 million.
